Belmont, CA, United States of America

Matthew Burdett

This inventor holds 1 USPTO granted patent. Top assignee: Sunesis Pharmaceuticals, Inc.. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Burdett. Retrieved from https://idiyas.com/inventor/matthew-burdett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Matthew Burdett - Innovator in Pharmaceutical Research

Introduction

Matthew Burdett is a notable inventor based in Belmont, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of small molecule inhibitors.

Latest Patents

Matthew holds 1 patent for his invention titled "Small molecule inhibitors of caspases." This patent provides compounds having formula (I), which are essential in advancing therapeutic options in various medical conditions.

Career Highlights

Matthew is currently associated with Sunesis Pharmaceuticals, Inc., where he applies his expertise in drug development and innovation. His work focuses on creating effective treatments that can improve patient outcomes.

Collaborations

He collaborates with talented professionals in his field, including Ingrid Choong and Warren L DeLano. These partnerships enhance the research and development efforts at Sunesis Pharmaceuticals.

Conclusion

Matthew Burdett's contributions to pharmaceutical research and his innovative patents highlight his commitment to advancing medical science. His work continues to impact the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…